Research ExplorerPublicationsCardiopulmonary Bypass has No Significant Impact on Survival...

Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy

Standard

Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy : Multi-Institutional Analysis. / Nguyen, Hao G; Tilki, Derya; Dall'Era, Marc A; Durbin-Johnson, Blythe; Carballido, Joaquín A; Chandrasekar, Thenappan; Chromecki, Thomas; Ciancio, Gaetano; Daneshmand, Siamak; Gontero, Paolo; Gonzalez, Javier; Haferkamp, Axel; Hohenfellner, Markus; Huang, William C; Espinós, Estefania Linares; Mandel, Philipp; Martinez-Salamanca, Juan I; Master, Viraj A; McKiernan, James M; Montorsi, Francesco; Novara, Giacomo; Pahernik, Sascha; Palou, Juan; Pruthi, Raj S; Rodriguez-Faba, Oscar; Russo, Paul; Scherr, Douglas S; Shariat, Shahrokh F; Spahn, Martin; Terrone, Carlo; Vergho, Daniel; Wallen, Eric M; Xylinas, Evanguelos; Zigeuner, Richard; Libertino, John A; Evans, Christopher P.

In: J UROLOGY, Vol. 194, No. 2, 08.2015, p. 304-308.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Nguyen, HG, Tilki, D, Dall'Era, MA, Durbin-Johnson, B, Carballido, JA, Chandrasekar, T, Chromecki, T, Ciancio, G, Daneshmand, S, Gontero, P, Gonzalez, J, Haferkamp, A, Hohenfellner, M, Huang, WC, Espinós, EL, Mandel, P, Martinez-Salamanca, JI, Master, VA, McKiernan, JM, Montorsi, F, Novara, G, Pahernik, S, Palou, J, Pruthi, RS, Rodriguez-Faba, O, Russo, P, Scherr, DS, Shariat, SF, Spahn, M, Terrone, C, Vergho, D, Wallen, EM, Xylinas, E, Zigeuner, R, Libertino, JA & Evans, CP 2015, 'Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis', J UROLOGY, vol. 194, no. 2, pp. 304-308. https://doi.org/10.1016/j.juro.2015.02.2948

APA

Nguyen, H. G., Tilki, D., Dall'Era, M. A., Durbin-Johnson, B., Carballido, J. A., Chandrasekar, T., Chromecki, T., Ciancio, G., Daneshmand, S., Gontero, P., Gonzalez, J., Haferkamp, A., Hohenfellner, M., Huang, W. C., Espinós, E. L., Mandel, P., Martinez-Salamanca, J. I., Master, V. A., McKiernan, J. M., ... Evans, C. P. (2015). Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J UROLOGY, 194(2), 304-308. https://doi.org/10.1016/j.juro.2015.02.2948

Vancouver

Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T et al. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J UROLOGY. 2015 Aug;194(2):304-308. https://doi.org/10.1016/j.juro.2015.02.2948

Bibtex

@article{2c628b01bd234a75828fcec3abaca6d6,
title = "Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis",
abstract = "PURPOSE: The impact of cardiopulmonary bypass in level III-IV tumor thrombectomy on surgical and oncologic outcomes is unknown. We determine the impact of cardiopulmonary bypass on overall and cancer specific survival, as well as surgical complication rates and immediate outcomes in patients undergoing nephrectomy and level III-IV tumor thrombectomy with or without cardiopulmonary bypass.MATERIALS AND METHODS: We retrospectively analyzed 362 patients with renal cell cancer and with level III or IV tumor thrombus from 1992 to 2012 at 22 U.S. and European centers. Cox proportional hazards models were used to compare overall and cancer specific survival between patients with and without cardiopulmonary bypass. Perioperative mortality and complication rates were assessed using logistic regression analyses.RESULTS: Median overall survival was 24.6 months in noncardiopulmonary bypass cases and 26.6 months in cardiopulmonary bypass cases. Overall survival and cancer specific survival did not differ significantly in both groups on univariate analysis or when adjusting for known risk factors. On multivariate analysis no significant differences were seen in hospital length of stay, Clavien 1-4 complication rate, intraoperative or 30-day mortality and cancer specific survival. Limitations include the retrospective nature of the study.CONCLUSIONS: In our multi-institutional analysis the use of cardiopulmonary bypass did not significantly impact cancer specific survival or overall survival in patients undergoing nephrectomy and level III or IV tumor thrombectomy. Neither approach was independently associated with increased mortality on multivariate analysis. Greater surgical complications were not independently associated with the use of cardiopulmonary bypass.",
keywords = "Carcinoma, Renal Cell, Cardiopulmonary Bypass, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Neoplastic Cells, Circulating, Nephrectomy, Retrospective Studies, Survival Rate, Thrombectomy, United States, Vena Cava, Inferior, Venous Thrombosis, Journal Article, Multicenter Study",
author = "Nguyen, {Hao G} and Derya Tilki and Dall'Era, {Marc A} and Blythe Durbin-Johnson and Carballido, {Joaqu{\'i}n A} and Thenappan Chandrasekar and Thomas Chromecki and Gaetano Ciancio and Siamak Daneshmand and Paolo Gontero and Javier Gonzalez and Axel Haferkamp and Markus Hohenfellner and Huang, {William C} and Espin{\'o}s, {Estefania Linares} and Philipp Mandel and Martinez-Salamanca, {Juan I} and Master, {Viraj A} and McKiernan, {James M} and Francesco Montorsi and Giacomo Novara and Sascha Pahernik and Juan Palou and Pruthi, {Raj S} and Oscar Rodriguez-Faba and Paul Russo and Scherr, {Douglas S} and Shariat, {Shahrokh F} and Martin Spahn and Carlo Terrone and Daniel Vergho and Wallen, {Eric M} and Evanguelos Xylinas and Richard Zigeuner and Libertino, {John A} and Evans, {Christopher P}",
note = "Copyright {\textcopyright} 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.",
year = "2015",
month = aug,
doi = "10.1016/j.juro.2015.02.2948",
language = "English",
volume = "194",
pages = "304--308",
journal = "J UROLOGY",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy

T2 - Multi-Institutional Analysis

AU - Nguyen, Hao G

AU - Tilki, Derya

AU - Dall'Era, Marc A

AU - Durbin-Johnson, Blythe

AU - Carballido, Joaquín A

AU - Chandrasekar, Thenappan

AU - Chromecki, Thomas

AU - Ciancio, Gaetano

AU - Daneshmand, Siamak

AU - Gontero, Paolo

AU - Gonzalez, Javier

AU - Haferkamp, Axel

AU - Hohenfellner, Markus

AU - Huang, William C

AU - Espinós, Estefania Linares

AU - Mandel, Philipp

AU - Martinez-Salamanca, Juan I

AU - Master, Viraj A

AU - McKiernan, James M

AU - Montorsi, Francesco

AU - Novara, Giacomo

AU - Pahernik, Sascha

AU - Palou, Juan

AU - Pruthi, Raj S

AU - Rodriguez-Faba, Oscar

AU - Russo, Paul

AU - Scherr, Douglas S

AU - Shariat, Shahrokh F

AU - Spahn, Martin

AU - Terrone, Carlo

AU - Vergho, Daniel

AU - Wallen, Eric M

AU - Xylinas, Evanguelos

AU - Zigeuner, Richard

AU - Libertino, John A

AU - Evans, Christopher P

N1 - Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2015/8

Y1 - 2015/8

N2 - PURPOSE: The impact of cardiopulmonary bypass in level III-IV tumor thrombectomy on surgical and oncologic outcomes is unknown. We determine the impact of cardiopulmonary bypass on overall and cancer specific survival, as well as surgical complication rates and immediate outcomes in patients undergoing nephrectomy and level III-IV tumor thrombectomy with or without cardiopulmonary bypass.MATERIALS AND METHODS: We retrospectively analyzed 362 patients with renal cell cancer and with level III or IV tumor thrombus from 1992 to 2012 at 22 U.S. and European centers. Cox proportional hazards models were used to compare overall and cancer specific survival between patients with and without cardiopulmonary bypass. Perioperative mortality and complication rates were assessed using logistic regression analyses.RESULTS: Median overall survival was 24.6 months in noncardiopulmonary bypass cases and 26.6 months in cardiopulmonary bypass cases. Overall survival and cancer specific survival did not differ significantly in both groups on univariate analysis or when adjusting for known risk factors. On multivariate analysis no significant differences were seen in hospital length of stay, Clavien 1-4 complication rate, intraoperative or 30-day mortality and cancer specific survival. Limitations include the retrospective nature of the study.CONCLUSIONS: In our multi-institutional analysis the use of cardiopulmonary bypass did not significantly impact cancer specific survival or overall survival in patients undergoing nephrectomy and level III or IV tumor thrombectomy. Neither approach was independently associated with increased mortality on multivariate analysis. Greater surgical complications were not independently associated with the use of cardiopulmonary bypass.

AB - PURPOSE: The impact of cardiopulmonary bypass in level III-IV tumor thrombectomy on surgical and oncologic outcomes is unknown. We determine the impact of cardiopulmonary bypass on overall and cancer specific survival, as well as surgical complication rates and immediate outcomes in patients undergoing nephrectomy and level III-IV tumor thrombectomy with or without cardiopulmonary bypass.MATERIALS AND METHODS: We retrospectively analyzed 362 patients with renal cell cancer and with level III or IV tumor thrombus from 1992 to 2012 at 22 U.S. and European centers. Cox proportional hazards models were used to compare overall and cancer specific survival between patients with and without cardiopulmonary bypass. Perioperative mortality and complication rates were assessed using logistic regression analyses.RESULTS: Median overall survival was 24.6 months in noncardiopulmonary bypass cases and 26.6 months in cardiopulmonary bypass cases. Overall survival and cancer specific survival did not differ significantly in both groups on univariate analysis or when adjusting for known risk factors. On multivariate analysis no significant differences were seen in hospital length of stay, Clavien 1-4 complication rate, intraoperative or 30-day mortality and cancer specific survival. Limitations include the retrospective nature of the study.CONCLUSIONS: In our multi-institutional analysis the use of cardiopulmonary bypass did not significantly impact cancer specific survival or overall survival in patients undergoing nephrectomy and level III or IV tumor thrombectomy. Neither approach was independently associated with increased mortality on multivariate analysis. Greater surgical complications were not independently associated with the use of cardiopulmonary bypass.

KW - Carcinoma, Renal Cell

KW - Cardiopulmonary Bypass

KW - Female

KW - Humans

KW - Kidney Neoplasms

KW - Male

KW - Middle Aged

KW - Neoplastic Cells, Circulating

KW - Nephrectomy

KW - Retrospective Studies

KW - Survival Rate

KW - Thrombectomy

KW - United States

KW - Vena Cava, Inferior

KW - Venous Thrombosis

KW - Journal Article

KW - Multicenter Study

U2 - 10.1016/j.juro.2015.02.2948

DO - 10.1016/j.juro.2015.02.2948

M3 - SCORING: Journal article

C2 - 25797392

VL - 194

SP - 304

EP - 308

JO - J UROLOGY

JF - J UROLOGY

SN - 0022-5347

IS - 2

ER -